Amylyx Pharmaceuticals, Inc.AMLXNASDAQ
Loading
AMLX Revenue Growth (YoY Quarterly)•+0.00%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+0.00%
+100.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+37.86%
+0.8pp
+37.86%
+0.8pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.61% | -100.00% | +0.00% | -100.00% | +0.00% |
| Gross Profit Growth | -100.67% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | -1911.81% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | -2202.07% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -893.62% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -883.48% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -904.09% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.75% | +26.30% | +31.04% | +37.07% | +37.86% |
| Weighted Average Shares Diluted Growth | -0.87% | +26.30% | +31.04% | +37.07% | +37.86% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -535.45% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -547.35% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -98.88% | -98.53% | -95.04% | -86.60% | -80.31% |
| Inventory Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -62.58% | -47.38% | -41.41% | +44.68% | +71.79% |
| Book Value per Share Growth | -62.64% | -50.84% | -50.97% | +23.45% | +34.39% |
| Debt Growth | -53.25% | -62.59% | +89.81% | +131.20% | +200.71% |
| R&D Expense Growth | -49.03% | -39.58% | +17.01% | -6.51% | -7.81% |
| SG&A Expenses Growth | -67.27% | -72.85% | -27.75% | -9.29% | -9.97% |
1 / 4